The alert addresses 3 falsified batches of products of the semaglutide class of medicines , which have been detected in Brazil in October 2023, the United Kingdom of Great Britain and Northern Ireland in October 2023, and the United States of America in December 2023.
The semaglutides, including the specific brand product that has been falsified, are prescribed to people with type 2 diabetes to lower their blood sugar levels. Semaglutides also reduce the risk of cardiovascular events. WHO has been observing increased demand for these medicines as well as reports on falsification. These falsified products could have harmful effects on people’s health; if the products don’t have the necessary raw components, falsified medicines can lead to health complications resulting from unmanaged blood glucose levels or weight. In other cases, another undeclared active ingredient may be contained in the injection device, e.g.
Also, there are more affordable treatments available for diabetes, with similar effects to those of semaglutides on blood sugar and cardiovascular risk.Experts say less than 6 hours sleep daily raises type 2 diabetes risk
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: PremiumTimesng - 🏆 3. / 78 Read more »
Source: GuardianNigeria - 🏆 1. / 94 Read more »